2883634-40-8
Chemical Structure
Eloralintide
Synonym(s): LY-3841136
- CAS No.: 2883634-40-8
- Formula:C201H319N49O65S2
- Molecular Weight:4526.10
SMILES: OC1=CC=C(C[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@H]2N(CCC2)C([C@H]3N(CCC3)C([C@@H](NC([C@@H](NC([C@H]4N(CCC4)C(CNC([C@@H](NC([C@@H](N(C)C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@](C)(NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC5=O)CC(N)=O)=O)[C@@H](C)O)=O)C)=O)[C@@H](C)O)=O)CSCSC[C@@H]5NC(CC[C@H](N)C(O)=O)=O)=O)C)=O)[C@@H](C)O)=O)=O)CCCN)=O)CC(C)C)=O)C)=O)CCC(O)=O)=O)CC6=CC=CC=C6)=O)CC(C)C)=O)C(C)C)=O)CCCNC(N)=N)=O)CO)=O)CO)=O)CC(N)=O)=O)CC(N)=O)=O)CC7=CC=CC=C7)=O)=O)=O)CCCCNC(CC[C@H](NC(CC[C@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)C(O)=O)=O)=O)CC(C)C)=O)=O)=O)[C@@H](C)O)=O)CCC(O)=O)=O)C(C)C)=O)=O)CO)=O)CC(N)=O)=O)[C@@H](C)O)=O)C(N)=O)C=C1
Biological Activity: Eloralintide (LY-3841136) is an amylin receptor agonist with human AMY1R EC50 23.9 pM and human AMY3R EC50 253.8 pM. Eloralintide induces decreased appetite, reduced food intake, body weight and fat mass loss, prolonged plasma calcium2+ reduction, and weak conditioned taste avoidance. Eloralintide can be used for the research of obesity[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Eloralintide | 99.97% | Eloralintide (LY-3841136) is an amylin receptor agonist with human AMY1R EC50 23.9 pM and human AMY3R EC50 253.8 pM. Eloralintide induces decreased appetite, reduced food intake, body weight and fat mass loss, prolonged plasma calcium2+ reduction, and weak conditioned taste avoidance. Eloralintide can be used for the research of obesity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Bhattachar S, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obes Metab. Published online January 20, 2026. [Content Brief]
- [2]. DAVID IPSEN, et al. 86-OR: The Amylin Receptor Selective Agonist NN1213 Reduces Food Intake and Body Weight in Rats without Decreasing Calcium Plasma Levels.
- [3]. Briere DA, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025 Dec;102:102271. [Content Brief]
Keywords
